Sangui Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>SB</div>
SGBI -- USA Stock  

USD 0.013  0.0029  18.24%

Given the investment horizon of 30 days, and your above-average risk tolerance our recommendation regarding Sangui Biotech Intl is 'Hold'. Macroaxis provides Sangui Biotech buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SGBI positions. The advice algorithm takes into account all of Sangui Biotech Intl available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from SGBI buy-and-hold perspective. Additionally, take a look at Sangui Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Search Advice

 
Refresh

Time Horizon

Risk Tolerance

Execute Advice
Sell Sangui BiotechBuy Sangui Biotech
Cautious Hold

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Sangui Biotech Intl has a mean deviation of 10.49, semi deviation of 12.98, standard deviation of 23.48, variance of 551.25, downside variance of 1687.0 and semi variance of 168.55
We provide advice to complement the current expert consensus on Sangui Biotech. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Sangui Biotech Intl is not overpriced, please validate all Sangui Biotech fundamentals, including its cash and equivalents, as well as the relationship between the cash flow from operations and market capitalization . As Sangui Biotech Intl appears to be a penny stock we also recommend to double-check its price to earning numbers.

Sangui Biotech Trading Alerts and Improvement Suggestions

Sangui Biotech Intl appears to be very risky and stock price may revert if volatility continues
Sangui Biotech Intl has some characteristics of a very speculative penny stock
The company currently holds 638.53 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Intl has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
The entity reported the previous year revenue of 45.75 K. Net Loss for the year was (234.27 K) with profit before overhead, payroll, taxes, and interest of 88 K.
Sangui Biotech Intl currently holds about 11.57 K in cash with (208.68 K) of positive cash flow from operations.
Roughly 24.0% of Sangui Biotech outstanding shares are owned by corporate insiders
Latest headline from simplywall.st: How Much Did Sangui Biotech International, Inc.s CEO Pocket Last Year - Simply Wall St

Sangui Biotech Returns Distribution Density

The chart of the probability distribution of Sangui Biotech stock daily returns describes the distribution of returns around its average expected value. We use Sangui Biotech Intl' stock's Value At Risk and its Upside Potential as a relative measure of the distribution. The distribution of Sangui Biotech returns is essential to provide solid investment advice for Sangui Biotech stock.
Mean Return2.97Value At Risk-9.72
Potential Upside47.77Standard Deviation23.48
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sangui Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Sangui Biotech Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sangui Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sangui Biotech stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sangui stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
=2.70
β
Beta against DOW=1.42
σ
Overall volatility
=24.38
Ir
Information ratio =0.12

Sangui Biotech Volatility Alert

Sangui Biotech Intl is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Sangui Biotech implied risk. Sangui Biotech Intl is a penny stock. Although Sangui Biotech may be in fact a good investment, many penny otc stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Sangui Biotech Intl. We encourage investors to look for the signals such us message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
    
 Better Than Average     
    
 Worse Than Average Compare Sangui Biotech to competition

Sangui Biotech Fundamental Vs Peers

FundamentalsSangui BiotechPeer Average
Return On Asset(169.30) %(0.14) %
Operating Margin(524.04) %(5.51) %
Current Valuation2.61 M16.62 B
Shares Outstanding202.73 M571.82 M
Shares Owned by Insiders23.68 %10.09 %
Price to Earning(18.33) X28.72 X
Price to Book17.00 X9.51 X
Price to Sales57.39 X11.42 X
Revenue45.75 K9.43 B
Gross Profit88 K27.38 B
Net Income(234.27 K)570.98 M
Cash and Equivalents11.57 K2.7 B
Total Debt638.53 K5.32 B
Debt to Equity0.05 %48.70 %
Current Ratio0.07 X2.16 X
Cash Flow from Operations(208.68 K)971.22 M
Earnings Per Share(0.001) X3.12 X
Number of Employees118.84 K
Beta0.85-0.15
Market Capitalization2.63 M19.03 B
Retained Earnings(37 M)9.33 B
Z Score2.48.72

About Sangui Biotech Buy or Sell Advice

When is the right time to buy or sell Sangui Biotech Intl? Buying stocks such as Sangui Biotech isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily bases. Although Sangui Biotech investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply. Please read more on our stock advisor page.

Did You Try This Idea?

Run IT Thematic Idea Now

IT
IT Theme
Information Technology (IT) companies and IT service providers across different domains. IT theme has 30 constituents.
View All  Next Launch IT
Additionally, take a look at Sangui Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page